Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Genetically-modified chickens offer hope for cheaper drugs
Chickens could be used as a cheaper method for producing high-quality research drugs.

New method produces therapeutic proteins as part of the egg white

Researchers at the University of Edinburgh’s Roslin Institute have genetically-modified chickens to produce human proteins in their eggs.

It is hoped the method could one day offer a cost-effective solution for producing certain drugs, including therapies for treating cancer.

The team found that high quantities of the proteins needed for the drugs could be recovered from each egg using a purification system. The drugs they recovered worked as well as if the same proteins were produced using existing methods.

Their findings suggest that chickens could be used as a cheaper method for producing high-quality research drugs. Looking ahead it is also hoped that the drugs could be used in patients.

The team set out to produce high-quality proteins for use in scientific research. They did not witness any adverse effects on the chickens themselves, which continued to lay eggs as normal.

Scientists already use eggs to produce vaccinations, such as the influenza vaccine. But the new method differs because the proteins are produced as part of the egg white.

In this study, three eggs were enough to develop a dose of the drug that is clinically relevant. With chickens laying up to around 300 eggs per year, researchers say the approach could be more cost-effective than current methods.

The two proteins the team have been focusing on are IFNalpha2a, which has powerful anti-cancer and anti-inflammatory effects, and macrophage-CSF, which can stimulate the repair of damaged tissues.

Professor Helen Sang of the Roslin Institute said: “We are not yet producing medicines for people, but this study shows that chickens are commercially viable for producing proteins suitable for drug discovery studies and other applications in biotechnology.”

Dr Lissa Herron, head of the Avian Biopharming Business Institute at Roslin Technologies, added: “We are excited to develop this technology to its full potential, not just for human therapies in the future but also in the fields of research and animal health.”

The findings are published in the journal BMC Biotechnology. 

Become a member or log in to add this story to your CPD history

FIVP publishes CMA Compliance Checklist

News Story 1
 FIVP has published a CMA Compliance Checklist to support independent practices with the Market Investigation Order.

The document includes deadlines for small and large businesses, with tick boxes for each of the tasks. The organisation also invites practices to contact them for support with requirements.

Rita Dingwall, FIVP chair, said: FIVP appreciates that navigating the new CMA requirements can feel daunting. We hope this checklist will make things a little easier, helping independent practices work through what is required with confidence. 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.